WO2002076460A2 - Reduction de la pression intra-oculaire au moyen de propentofylline - Google Patents

Reduction de la pression intra-oculaire au moyen de propentofylline Download PDF

Info

Publication number
WO2002076460A2
WO2002076460A2 PCT/US2002/005456 US0205456W WO02076460A2 WO 2002076460 A2 WO2002076460 A2 WO 2002076460A2 US 0205456 W US0205456 W US 0205456W WO 02076460 A2 WO02076460 A2 WO 02076460A2
Authority
WO
WIPO (PCT)
Prior art keywords
propentofylline
composition
iop
additional agent
glaucoma
Prior art date
Application number
PCT/US2002/005456
Other languages
English (en)
Other versions
WO2002076460A3 (fr
Inventor
Iok-Hou Pang
Mark R. Hellberg
Abbot F. Clark
Peggy E. Hellberg
Debra L. Shade
Original Assignee
Alcon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon, Inc. filed Critical Alcon, Inc.
Priority to JP2002574975A priority Critical patent/JP2004528310A/ja
Priority to BR0208146-6A priority patent/BR0208146A/pt
Priority to MXPA03008491A priority patent/MXPA03008491A/es
Priority to CA002434691A priority patent/CA2434691A1/fr
Priority to EP02719062A priority patent/EP1370267A2/fr
Priority to US10/250,326 priority patent/US20040110776A1/en
Publication of WO2002076460A2 publication Critical patent/WO2002076460A2/fr
Publication of WO2002076460A3 publication Critical patent/WO2002076460A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des méthodes propres à réduire la tension intra-oculaire au moyen de propentofylline.
PCT/US2002/005456 2001-03-21 2002-02-22 Reduction de la pression intra-oculaire au moyen de propentofylline WO2002076460A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002574975A JP2004528310A (ja) 2001-03-21 2002-02-22 眼内圧を制御するためのプロペントフィリンの使用
BR0208146-6A BR0208146A (pt) 2001-03-21 2002-02-22 Uso de propentofilina para controlar pressão intra-ocular
MXPA03008491A MXPA03008491A (es) 2001-03-21 2002-02-22 El uso de propentofilina para controlar la presion intraocular.
CA002434691A CA2434691A1 (fr) 2001-03-21 2002-02-22 Reduction de la pression intra-oculaire au moyen de propentofylline
EP02719062A EP1370267A2 (fr) 2001-03-21 2002-02-22 Reduction de la pression intra-oculaire au moyen de propentofylline
US10/250,326 US20040110776A1 (en) 2002-02-22 2002-02-22 Use of propentofylline to control intraocular pressure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27754801P 2001-03-21 2001-03-21
US60/277,548 2001-03-21

Publications (2)

Publication Number Publication Date
WO2002076460A2 true WO2002076460A2 (fr) 2002-10-03
WO2002076460A3 WO2002076460A3 (fr) 2003-04-03

Family

ID=23061335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005456 WO2002076460A2 (fr) 2001-03-21 2002-02-22 Reduction de la pression intra-oculaire au moyen de propentofylline

Country Status (7)

Country Link
EP (1) EP1370267A2 (fr)
JP (1) JP2004528310A (fr)
AR (1) AR032812A1 (fr)
BR (1) BR0208146A (fr)
CA (1) CA2434691A1 (fr)
MX (1) MXPA03008491A (fr)
WO (1) WO2002076460A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016043A1 (fr) * 2008-08-05 2010-02-11 University College Cork, National University Of Ireland, Cork Traitement de la dégénérescence de la rétine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010016043A1 (fr) * 2008-08-05 2010-02-11 University College Cork, National University Of Ireland, Cork Traitement de la dégénérescence de la rétine

Also Published As

Publication number Publication date
JP2004528310A (ja) 2004-09-16
CA2434691A1 (fr) 2002-10-03
MXPA03008491A (es) 2003-12-08
WO2002076460A3 (fr) 2003-04-03
BR0208146A (pt) 2004-03-02
AR032812A1 (es) 2003-11-26
EP1370267A2 (fr) 2003-12-17

Similar Documents

Publication Publication Date Title
CA2496797C (fr) Agent therapeutique contre le glaucome a base d'inhibiteurs de rho kinase et de prostaglandines
US20090312390A1 (en) Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
US20060111388A1 (en) Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
AU724923B2 (en) Therapeutic treatment for VEGF related occular diseases
EP1740164B1 (fr) Statines pour le traitement de l'hypertension oculaire et du glaucome
KR20080016556A (ko) 각결막 장애의 예방 또는 치료제
EP1752456B1 (fr) Médicament permettant de restaurer la perception de la cornée contenant un composé d'amide
US7972612B2 (en) Remedy for glaucoma comprising Rho kinase inhibitor and β-blocker
WO1997040831A9 (fr) Traitement therapeutique pour les maladies oculaires liees au vegf
RU2324483C2 (ru) Ингибиторы гистондеацетилазы для лечения дегенеративных заболеваний глаз
KR100499903B1 (ko) 안압 제어 및 녹내장 치료용 5ｈｔ2 효능제
AU2001216071A1 (en) 5HT2 agonists for controlling IOP and treating glaucoma
EP1131073B1 (fr) Utilisation de derives de staurosporine dans le traitement des neoformations de vaisseaux sanguins oculaires
US6214819B1 (en) Method for treating ocular neovascular diseases
EP1370267A2 (fr) Reduction de la pression intra-oculaire au moyen de propentofylline
US20040110776A1 (en) Use of propentofylline to control intraocular pressure
AU2002250168A1 (en) Use of propentofylline to control intraocular pressure
EP2266559A1 (fr) Agent thérapeutique pour maladie ophtalmique
US6927233B1 (en) 5ht2 agonists for controlling IOP and treating glaucoma
KR20080111092A (ko) 고안압증 조절 및 녹내장의 치료를 위한 프레닐트랜스퍼라아제 억제제
KR20050013238A (ko) 각결막 상피세포 장해치료약 또는 예방약
US6534475B1 (en) Use of TIMP-3 inducers of TIMP-3 expression, and TIMP-3 mimetics to treat ocular neovascularization
Lee et al. Medical therapy for glaucoma
RENGARAJ VENKATESH COMMONLY PRESCRIBED GLAUCOMA EYE DROPS AND ORAL MEDICATIONS
Clode OCULAR HYPOTENSIVE AGENTS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP KR MX PH PL US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10250326

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002250168

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2434691

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002719062

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002574975

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008491

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2002719062

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002719062

Country of ref document: EP